MA38358A1 - Formulations de composés organiques - Google Patents

Formulations de composés organiques

Info

Publication number
MA38358A1
MA38358A1 MA38358A MA38358A MA38358A1 MA 38358 A1 MA38358 A1 MA 38358A1 MA 38358 A MA38358 A MA 38358A MA 38358 A MA38358 A MA 38358A MA 38358 A1 MA38358 A1 MA 38358A1
Authority
MA
Morocco
Prior art keywords
formulations
organic compounds
pharmaceutically acceptable
present
relates
Prior art date
Application number
MA38358A
Other languages
English (en)
Other versions
MA38358B1 (fr
Inventor
Charu Kochhar
Jacques Quinton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38358A1 publication Critical patent/MA38358A1/fr
Publication of MA38358B1 publication Critical patent/MA38358B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136—Balloons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/1204—Type of occlusion temporary occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1002—Balloon catheters characterised by balloon shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12068—Details concerning the detachment of the occluding device from the introduction device detachable by heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12086—Details concerning the detachment of the occluding device from the introduction device magnetically detachable

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Surgical Instruments (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques solides comprenant le composé inhibiteur de phosphatidylinositol 3-kinase 4-(trifluorométhyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine ou un sel pharmaceutiquement acceptable de celui-ci, du stéaryl-fumarate de sodium, et facultativement au moins un véhicule pharmaceutiquement acceptable additionnel. La présente invention concerne en outre les procédés pour leur préparation et leur utilisation en tant que médicaments pour le traitement du cancer.
MA38358A 2013-03-06 2014-03-04 Formulations de composés organiques MA38358B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773492P 2013-03-06 2013-03-06
PCT/IB2014/059424 WO2014136048A1 (fr) 2013-03-06 2014-03-04 Formulations de composés organiques

Publications (2)

Publication Number Publication Date
MA38358A1 true MA38358A1 (fr) 2016-11-30
MA38358B1 MA38358B1 (fr) 2017-07-31

Family

ID=50342366

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38358A MA38358B1 (fr) 2013-03-06 2014-03-04 Formulations de composés organiques

Country Status (28)

Country Link
US (2) US9474534B2 (fr)
EP (1) EP2964200B1 (fr)
JP (1) JP6313343B2 (fr)
KR (1) KR102233757B1 (fr)
CN (1) CN105073099B (fr)
AR (2) AR095032A1 (fr)
AU (1) AU2014224238B2 (fr)
BR (1) BR112015021097B1 (fr)
CA (1) CA2904032C (fr)
CL (1) CL2015002466A1 (fr)
EA (1) EA028301B1 (fr)
ES (1) ES2634020T3 (fr)
IL (1) IL240579B (fr)
JO (1) JO3256B1 (fr)
MA (1) MA38358B1 (fr)
MX (1) MX370175B (fr)
MY (1) MY174648A (fr)
NZ (1) NZ711015A (fr)
PE (1) PE20151607A1 (fr)
PH (1) PH12015501945A1 (fr)
PL (1) PL2964200T3 (fr)
PT (1) PT2964200T (fr)
SG (1) SG11201506392VA (fr)
TN (1) TN2015000386A1 (fr)
TW (1) TW201442712A (fr)
UA (1) UA114948C2 (fr)
WO (1) WO2014136048A1 (fr)
ZA (1) ZA201505830B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498604B2 (en) 1997-11-12 2016-11-22 Genesis Technologies Llc Medical device and method
US10335577B2 (en) 2010-05-19 2019-07-02 Nfinium Vascular Technologies, Llc Augmented delivery catheter and method
US9561094B2 (en) 2010-07-23 2017-02-07 Nfinium Vascular Technologies, Llc Devices and methods for treating venous diseases
EP3151904A4 (fr) 2014-06-04 2018-02-14 Nfinium Vascular Technologies, LLC Dispositif vasculaire à faible force radiale et procédé d'occlusion
IL256299B2 (en) * 2015-06-30 2023-11-01 Genentech Inc Immediate-release tablets containing a drug and processes for creating the tablets
FI130702B1 (en) * 2018-12-18 2024-01-26 Miikka Frant Device suitable for insertion into the vein of a human patient
WO2020242795A1 (fr) * 2019-05-24 2020-12-03 Eisai R&D Management Co., Ltd. Procédé de traitement du cancer avec une forme posologique orale d'un inhibiteur du récepteur alpha des oestrogènes
EP4199798A1 (fr) * 2020-09-27 2023-06-28 Boston Scientific Scimed Inc. Dispositifs de guidage expansibles, systèmes, et procédés
WO2022170187A1 (fr) 2021-02-05 2022-08-11 Pyne Devaraj Dispositif et méthodes d'embolisation à ballonnet détachable

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE206304T1 (de) * 1995-12-27 2001-10-15 Janssen Pharmaceutica Nv Bioadhesive feste arzneimittelform
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
WO1999039649A1 (fr) * 1998-02-10 1999-08-12 Dubrul William R Appareil d'occlusion, d'ancrage et de mise en tension flottant et procedes d'utilisation
US6066157A (en) 1998-09-16 2000-05-23 Medtronics Ave, Inc. Anchor joint for coaxial balloon dilatation catheter
US6368338B1 (en) 1999-03-05 2002-04-09 Board Of Regents, The University Of Texas Occlusion method and apparatus
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
US7618435B2 (en) * 2003-03-04 2009-11-17 Nmt Medical, Inc. Magnetic attachment systems
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20110050549A (ko) * 2008-09-03 2011-05-13 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 이를 포함하는 제약 제제
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
IN2012DN03271A (fr) * 2009-10-23 2015-10-23 Merck Sharp & Dohme
US8992540B2 (en) 2010-07-22 2015-03-31 Kyphon Sarl Adjustable surgical instruments and methods of use and fabrication
WO2012060847A1 (fr) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procédés de traitement de la myélofibrose
EP3127492B1 (fr) 2011-06-03 2023-01-18 Covidien LP Implant embolique
WO2014164535A1 (fr) 2013-03-11 2014-10-09 Ferry Steven J Fil-guide/dispositif d'occlusion partielle pour course intraluminale

Also Published As

Publication number Publication date
CA2904032C (fr) 2021-02-16
TN2015000386A1 (en) 2017-01-03
PL2964200T3 (pl) 2017-09-29
AU2014224238B2 (en) 2016-07-14
IL240579A0 (en) 2015-09-24
EP2964200B1 (fr) 2017-04-19
US20160045202A1 (en) 2016-02-18
WO2014136048A1 (fr) 2014-09-12
UA114948C2 (uk) 2017-08-28
BR112015021097B1 (pt) 2022-08-30
TW201442712A (zh) 2014-11-16
PH12015501945B1 (en) 2016-01-11
EP2964200A1 (fr) 2016-01-13
BR112015021097A2 (pt) 2017-07-18
US9474534B2 (en) 2016-10-25
CL2015002466A1 (es) 2016-03-04
CN105073099A (zh) 2015-11-18
MA38358B1 (fr) 2017-07-31
MY174648A (en) 2020-05-05
KR102233757B1 (ko) 2021-03-30
NZ711015A (en) 2020-02-28
AR095032A1 (es) 2015-09-16
AU2014224238A1 (en) 2015-09-03
CN105073099B (zh) 2018-10-26
AR128459A2 (es) 2024-05-08
HK1212244A1 (en) 2016-06-10
IL240579B (en) 2019-08-29
JP6313343B2 (ja) 2018-04-18
CA2904032A1 (fr) 2014-09-12
ES2634020T3 (es) 2017-09-26
US20160015643A1 (en) 2016-01-21
PE20151607A1 (es) 2015-11-26
EA201591649A1 (ru) 2016-01-29
EA028301B1 (ru) 2017-10-31
KR20150123248A (ko) 2015-11-03
MX370175B (es) 2019-12-04
US10342547B2 (en) 2019-07-09
PT2964200T (pt) 2017-07-25
ZA201505830B (en) 2017-07-26
SG11201506392VA (en) 2015-09-29
JP2016510065A (ja) 2016-04-04
MX2015011705A (es) 2016-05-18
PH12015501945A1 (en) 2016-01-11
JO3256B1 (ar) 2018-09-16

Similar Documents

Publication Publication Date Title
MA38358B1 (fr) Formulations de composés organiques
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA40769B1 (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
BR112018011376A2 (pt) composição farmacêutica que compreende um inibi-dor de urat1 potente
MA42811A (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39163B1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA37849A1 (fr) Dérivés de diazépinone à utiliser pour le traitement du syndrome de l'x fragile, de la maladie de parkinson ou de la maladie du reflux
EP2862573A4 (fr) Composition pour le traitement ou la prévention de maladies causées par une perméabilité vasculaire, contenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif
MA44383B1 (fr) Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer
FR3042191B1 (fr) Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives
MA38973A1 (fr) Aminohétéroaryles benzamides en tant qu'inhibiteurs de kinase
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses